Table 1 Univariate analysis of factors associated with acute kidney injury (AKI) during Polymyxin B in the treatment with CRO infections
Group | Total [n (%)] | AKI occur [n (%)] | P-value | AKI recovery [n (%)] | P-value |
|---|---|---|---|---|---|
Age (y) | |||||
65–75 y | 108 (50.2) | 35 (32.4) | 0.143 | 15 (42.9) | 0.194 |
> 75 y | 107 (49.8) | 45 (42.1) | 13 (28.9) | ||
Sex | |||||
Male | 148 (68.8) | 57 (38.5) | 0.557 | 17 (29.8) | 0.127 |
Female | 67 (31.2) | 23 (34.3) | 11 (47.8) | ||
APACHEII score | |||||
< 10 | 35 (16.3) | 5 (14.3) | 0.001 | 3 (60.0) | 0.059 |
10–20 | 104 (48.4) | 36 (34.6) | 16 (44.4) | ||
> 20 | 76 (35.3) | 39 (51.3) | 9 (23.1) | ||
Norepinephrine | |||||
No | 63 (29.3) | 16 (25.4) | 0.006 | 10 (62.5) | 0.019 |
≤ 0.1 μg/kg/min | 98 (45.6) | 35 (35.7) | 12 (34.3) | ||
> 0.1 μg/kg/min | 54 (25.1) | 29 (53.7) | 6 (20.7) | ||
Infection types | |||||
Pneumonia | 93 (43.2) | 35 (37.6) | 0.907 | 12 (34.3) | 1.000 |
BSIs | 49 (22.8) | 20 (40.8) | 7 (35) | ||
Intestinal infection | 38 (17.7) | 13 (34.2) | 5 (38.5) | ||
Other | 35 (16.3) | 12 (34.3) | 4 (33.3) | ||
Responsible pathogens | |||||
K.P | 75 (34.9) | 32 (42.7) | 0.792 | 10 (31.3) | 0.971 |
P.A | 57 (26.5) | 20 (35.1) | 7 (35.0) | ||
A.B | 23 (10.7) | 7 (30.4) | 3 (42.9) | ||
E.coli | 24 (11.2) | 8 (33.3) | 3 (37.5) | ||
Other | 36 (16.7) | 13 (36.1) | 5 (38.5) | ||
Polymyxin B daily dose | |||||
1.5 mg/kg/d | 65 (30.2) | 17 (26.2) | 0.028 | 5 (29.4) | 0.03 |
2.0 mg/kg/d | 96 (44.7) | 36 (37.5) | 18 (50.0) | ||
2.5 mg/kg/d | 54 (25.1) | 27 (50.0) | 5 (18.5) | ||
Initial treatment | |||||
Yes | 94 (43.7) | 32 (34.0) | 0.397 | 16 (50.0) | 0.022 |
No | 121 (56.3) | 48 (39.7) | 12 (25.0) | ||
Polymyxin B duration (d) | |||||
3–7 d | 64 (29.8) | 13 (20.3) | 0.001 | 5 (38.5) | 0.045 |
8–14 d | 73 (33.9) | 27 (37.0) | 14 (51.9) | ||
> 14 d | 78 (36.3) | 40 (51.3) | 9 (22.5) | ||
Polymyxin B monotherapy | |||||
Yes | 31 (14.4) | 10 (32.3) | 0.538 | 4 (40.0) | 0.725 |
No | 184 (85.6) | 70 (38.0) | 24 (34.3) | ||
Polymyxin B combination | |||||
Combined Carbapenems | 40 (21.7) | 16 (40.0) | 0.925 | 6 (25.0) | 0.872 |
Combined Tigecycline | 53 (28.8) | 20 (37.7) | 8 (40.0) | ||
Tigecycline + fosfomycin | 34 (18.5) | 12 (35.3) | 4 (33.3) | ||
Carbapenems + tigecycline | 22 (12.0) | 10 (45.4) | 3 (30.0) | ||
Other | 35 (19.0) | 12 (34.3) | 5 (41.7) | ||
Microbiological eradication | |||||
Yes | 95 (44.2) | 25 (26.3) | 0.003 | 10 (40.0) | 0.527 |
No | 120 (55.8) | 55 (45.8) | 18 (32.7) | ||
Clinical outcome | |||||
Cure | 109 (50.7) | 22 (20.2) | < 0.001 | 12 (54.5) | 0.024 |
Failure | 106 (49.3) | 58 (54.7) | 16 (27.6) | ||
Prognosis | |||||
Survival | 91 (42.3) | 15 (18.8) | 0.004 | 9 (60.0) | 0.024 |
Death | 124 (57.7) | 65 (52.4) | 19 (29.2) | ||